Hepion Pharmaceuticals Inc. Common Stock is a biopharmaceutical company focused on the development of innovative therapies for liver diseases, including non-alcoholic steatohepatitis (NASH). Through their novel drug candidates, they aim to address the unmet medical needs of patients with liver diseases and potentially improve their quality of life.
Notification